Source: Marketing Authorisation Holder Revision Year: 2019 Publisher: Les Laboratoires Servier France.
DAFLON 500 mg, film-coated tablet.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. |
Micronised purified flavonoid fraction: 500 mg
Corresponding to:
Diosmin: 90 per cent: 450 mg
Flavonoids expressed as hesperidin: 10 per cent: 50 mg
Mean humidity: 20 mg
For one film-coated tablet.
For a full list of excipients, see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Diosmin |
Diosmin (diosmetin 7-O-rutinoside), a flavone derivative also known as venosmine, is a glycoside of diosmetin, which in turn is the 4'-methoxy derivative of luteolin. Diosmin prolongs the vasoconstrictor effect of norepinephrine on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and venous stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from CVI. |
|
| Hesperidin |
|
| List of Excipients |
|---|
|
Sodium starch glycolate, microcrystalline cellulose, gelatine, magnesium stearate, talc, titanium. Film-coating: dioxide (E 171), glycerol, sodium lauryl sulphate, macrogol 6000, hypromellose, yellow iron oxide (E 172), red iron oxide (E 172). |
15 or 30 tablets in blister packs (PVC-Aluminium).
Not all pack sizes may be marketed.
Les Laboratoires Servier – France.
| Drug | Countries | |
|---|---|---|
| DAFLON | Austria, Brazil, Cyprus, Ecuador, Spain, France, Hong Kong, Malta, Nigeria, Singapore, Tunisia, Turkey |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
